Shares of Creative Medical Technology Holdings, Inc. CELZ skyrocketed more than 80% after it announced topline data from a two-year follow-up pilot study on StemSpine, a patented procedure for chronic ...
PHOENIX, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company pioneering ...
Creative Medical Technology (CELZ) announced one-year follow-up data from the AlloStem Type 2 Diabetes pilot study for late-stage patients. CELZ-201 is an off the shelf, ready-to-use universal and ...
2025 has been a landmark year for Creative Medical. With the support of the most comprehensive clinical, intellectual, and technological foundation in our Company’s history, we have evolved from proof ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback